Print this page    •   Back to Web version of article

Project Inform
Large Study Supports Earlier Treatment

By Paul Dalton

October 26, 2008

A large study presented at the joint 2008 ICAAC/IDSA in Washington, DC found that people who delayed starting HIV treatment until their CD4 counts fell below 350 were 70% more likely to experience a new AIDS-defining illness or death, than compared to those who began at CD4 counts of 350-500. This finding adds to the growing body of evidence supporting earlier treatment of HIV disease.

The researchers looked at the medical records of over 8,000 people from 22 research cohorts throughout the US and Canada between 1996 and 2006. Of those, almost 2,500 started HIV treatment with CD4 counts of 350-500, with the rest delaying treatment until sometime after their CD4 counts fell below 350. Current US guidelines recommend treatment for anyone with a CD4 count below 350.

Overall, people who started with lower CD4 counts were 1.7 times as likely to experience an AIDS-defining illness or death. Interestingly, the researchers found that neither a history of injection drug use nor HCV co-infection changed the increased risk associated with delayed treatment, although they did lead to more frequent illness and death overall. Not surprisingly older age was independently associated with an increased likelihood of illness or death, with each decade adding a 60% risk.

The researchers had no way of directly measuring adherence to treatment in this study. They did look at the likelihood that people in each group had undetectable HIV levels once they began treatment and found no significant difference between the groups.

Being a retrospective, combined cohort analysis limits the strength of this study’s observation. The presenters acknowledged this, and they said they took great pains to control for the kinds of biases that might influence their findings.

The same research team is analyzing this database to compare the rates of AIDS-defining illness and death between people who start HIV treatment with CD4 counts above and below 500. They expect to present those results soon.

In spite of the limitations of this kind of study, its findings are nonetheless important. Lacking a definitive, prospective, randomized study to answer this question, these studies may influence guidelines and prescribing practices.

This article was provided by Project Inform. Copyright Body Health Resources Corporation. All rights reserved.

You can find this article online by typing the following address into your Web browser:

Please Note: Knowledge about HIV changes rapidly. Note the date of this article's publication, and before treating patients or employing any therapies described in these materials, verify all information independently. If you are a patient, please consult a doctor or other medical professional before acting on any of the information presented in this article.

General Disclaimer: The Body is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through The Body should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your healthcare provider.